Off-label use of stents investigated

Mar 07, 2007

A federal committee is investigating the off label use of drug-coated heart stents by U.S. doctors, The Wall Street Journal reported Tuesday.

The U.S. House Committee on Oversight and Government reform has asked Boston Scientific and Johnson & Johnson, makers of the stents to submit marketing materials and clinical data for review.

About 60 percent of drug-coated stents, used to open clogged arteries, are prescribed outside of U.S. Food and Drug Administration boundaries, the Journal said.

Stents are commonly given to patients who have had heart attacks, despite a lack of rigorous testing in such patients, the report said.

While doctors are allowed to prescribe stents to off-label patients, "manufacturers can't encourage off-label use," the Journal said.

Copyright 2007 by United Press International

Explore further: India's meth addiction grows as criminals tap chemical hub

add to favorites email to friend print save as pdf

Related Stories

Google searches hold key to future market crashes

10 hours ago

A team of researchers from Warwick Business School and Boston University have developed a method to automatically identify topics that people search for on Google before subsequent stock market falls.

Recommended for you

Determine patient preferences by means of conjoint analysis

22 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0